Elizabeth White Email and Phone Number
I am a highly experienced biopharmaceutical senior executive with a unique ability to bridge business strategy and scientific innovation and have made a smooth transition from large pharma to entrepreneurial biotech. I have a very broad skill set gained through leadership roles over a 35+ year career spanning strategic planning, fundraising, business development, R&D, operations, corporate communications, commercial planning, and global brand management. With a specialized understanding of genetic medicines and gene therapy, I am experienced in many therapeutic areas with strong expertise in rare diseases (particularly neurodegenerative, neuromuscular, hematologic, cardiovascular, pulmonary, and metabolic). I am dedicated to helping emerging biotechnology companies successfully and efficiently translate their innovative technologies into accessible medicines that will help patients in need. I am currently CBO and Managing Partner of the Orphan Therapeutics Accelerator, a unique non-profit biotech focused on ultra-rare disease drug development and access. I am also CEO of White Biotech Solutions, a biotech consultancy focused on new company formation, corporate strategy, and business development. I recently served as Chief Business Officer and Senior Vice President of Operations for Renovacor, a public preclinical cardiovascular gene therapy company, where I helped to lead the growth and development of the organization and portfolio and led the business development efforts resulting in Renovacor's acquisition by Rocket Pharma. Prior to Renovacor, I was Chief Business and Strategy Officer for NeuExcell, a private preclinical gene therapy company focused on neurologic disorders, which was preceded by 20 years at Wyeth/Pfizer where I most recently led new product planning strategy as Assistant Vice President, Commercial Development, for Pfizer’s Rare Disease and Gene Therapy Business. I helped to build this business unit at Pfizer facilitating the completion of many successful licensing and acquisition deals, including the global collaboration and licensing deals with Spark Therapeutics and Sangamo Therapeutics and the acquisition of Bamboo Therapeutics, all of which have resulted in programs continuing to progress through Phase 3 human clinical trials. I am proud to be involved in the development of the life science ecosystem in the Philadelphia Region. I am also an Entrepreneur-in-Residence at Yale Ventures, an Industry Advisor for Rutgers University, and on the Board of Visitors for Allegheny College.
Orphan Therapeutics Accelerator
View-
Chief Business Officer And Managing PartnerOrphan Therapeutics Accelerator 2024 - PresentThe Orphan Therapeutics Accelerator is a non-profit biotech company focused on efficiently advancing promising “shelved” treatments for ultra-rare conditions through late-stage clinical development and approvals, and providing a viable commercial pathway to make them available to patients in need. Our model utilizes tax and other incentives to dramatically reduce up-front costs to obtain and develop therapeutic assets, features unique opportunities for collaboration across the orphan disease landscape, and leverages philanthropic and impact investment to establish a regenerative source of funding to build and sustain a pipeline of ultra-orphan drugs. We are currently seeking non-dilutive seed funding, actively working to in-license stalled gene therapy and other therapeutic assets from companies and academic institutions, and negotiating innovative agreements with rare disease-focused partner companies (e.g., CDMOs, CROs).
-
Ceo And FounderWhite Biotech Solutions, Llc 2023 - PresentBiotechnology consulting practice offering the following services: • New Company Formation, Financing, and Corporate Strategy• Business Development and Licensing / Acquisition Strategy• Strategic Business Planning and Budgeting• Operations, Program Management, and Drug Development Strategy• Portfolio Valuation and Decision Analysis• Global Market Analysis, Market Research, and Target Product Profile Development• Competitive Benchmarking and Sales Forecasting• Patient and Advocacy Community Engagement• Corporate Communications Strategy and Tacticshttps://whitebiotechsolutions.com/ -
Chief Business Officer & Senior Vice President Of OperationsRenovacor Jul 2021 - Dec 2022Led business development, strategic planning, and operations for Renovacor, Inc., a preclinical public gene therapy company focused on developing targeted therapies for rare genetic cardiovascular diseases. o Led business development efforts resulting in Rocket Pharma’s acquisition of Renovacor. o Managed corporate infrastructure development, program management, vendor contracts, and facilities expansion as the company went public on the NYSE, grew from 5 to 30 employees, and progressed the lead gene therapy program towards IND filing.o Led intellectual property strategy and portfolio management and executed significant Sponsored Research Agreement (SRAs) with multiple universities. o Partnered with CEO on preparations for Board meetings and presented to Board regularly.o Led commercial planning efforts including competitive intelligence, market research, epidemiology analysis, revenue forecasting, and target product profile development. o Facilitated Executive Committee meetings, internal communications, and tracking of goals and objectives. o Managed corporate communications strategy to deliver effective and timely external communications. -
Chief Business And Strategy OfficerNeuexcell Therapeutics Jun 2019 - Jul 2021King Of Prussia, Pennsylvania, UsLed strategic business planning for this pre-clinical start-up gene therapy company focused on neural trans-differentiation for neurodegenerative conditions including stroke, Huntington’s disease, ALS and Alzheimer’s disease. o Drove fundraising efforts that ultimately resulted in the successful execution of $10+ million Series Pre-A financing raise. o Built the corporate development strategy and led business development efforts resulting in execution of research collaboration and option agreement with Spark Therapeutics (a member of the Roche group) for development of a novel gene therapy for Huntington’s disease. Under this agreement, NeuExcell is eligible to receive up to ~$190 million in fees and milestones plus royalties, and Spark has the option to license exclusive worldwide rights for the HD program. o Evaluated and engaged contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and GLP-toxicology vendors to execute IND-enabling studies and first-in-human clinical studies. -
President And FounderWhite Biotech Solutions, Llc 2018 - 2019Business Development and New Product Planning Strategy Consultant focused on Rare Disease, Biologics and Gene Therapy.
-
Assistant Vice President, Commercial Development, Rare Disease And Gene TherapyPfizer 2011 - 2017New York, New York, UsLed the end-to-end new product planning strategy for Rare Disease and Gene Therapy Business Unit.• Enabled Pfizer's decision to establish a Business Unit focused on rare diseases and led the development of the cross-functional long-term strategic and operational plan that was endorsed by senior management. • Built Pfizer’s Rare Disease / Gene Therapy business by facilitating the completion of many successful licensing and acquisition deals, including partnerships with Spark Therapeutics and Sangamo Therapeutics, and the acquisition of Bamboo Therapeutics.• Directed numerous commercial analyses, providing insights on unmet medical needs, competitive differentiation and positioning, market value, and market access strategies to support target product profile development, clinical development planning, R&D portfolio prioritization, and in-licensing decisions. • Launched and led a working group focused on patient and advocacy engagement, finding innovative ways to involve patients throughout development, resulting in important clinical development plan improvements.• Strengthened Pfizer’s reputation by building and launching new rare disease and gene therapy communications strategy and tools, and by speaking at many key conferences.• Collaborated with corporate affairs colleagues on communication and policy issues, with a focus on value and pricing questions, resulting in consistent senior leader training and messaging. -
Assistant Vice President, Commercial Planning, Specialty CarePfizer 2009 - 2011New York, New York, UsLed the development and execution of new product planning strategy for seven disease areas within the Specialty Care Business Unit including inflammation, specialty cardiovascular disease, renal disease, hospital anti-infectives, hematology, transplant, and tissue repair. • Initiated and led cross-Pfizer team to drive coordination and communication between biosimilars and innovative biologics businesses, improving decision-making and execution. • Successfully delivered streamlined portfolio strategy for new Specialty Care Business Unit. • Managed team of directors with responsibility for improving development plans, portfolio prioritization and in-licensing decisions by incorporating important market perspectives.
-
Assistant Vice President, New Business / Portfolio ManagementPfizer 2008 - 2009New York, New York, UsLed development of long-term strategic business plans and optimization of development asset portfolios in the inflammation, oncology, and tissue repair therapeutic areas.• Led a team that provided commercial analysis and insights on unmet medical needs, competitive differentiation and positioning, market value, key stakeholders, and market access challenges for 18 development programs and many in-licensing opportunities.• Created and led matrix team that gained management consensus on biosimilars strategy.
-
Executive Director, Enbrel Worldwide Business ManagementPfizer 2006 - 2008New York, New York, UsBuilt global life cycle strategy and provided business leadership for Enbrel, the leading biotechnology brand in the world, with global sales exceeding $6B in 2008.• Created and led cross-indication Global Brand Leadership Team which gained senior management approval of comprehensive multi-indication, long-term life cycle strategy.• Delivered process improvements for the complex, cross-functional Enbrel Global Brand Teams resulting in improved decision-making internally and for external Amgen alliance.• Developed Enbrel biosimilars strategies, including management of first Wyeth biosimilars in China and Colombia and worldwide rollout of corporate biosimilar policy position.
-
Senior Director, Enbrel Global StrategyPfizer 2004 - 2006New York, New York, UsLed the long-term strategy for new Enbrel formulations, devices and dermatology business.• Collaborated with the manufacturing organization to lead efforts that resulted in corporate approval to develop pre-filled syringe, auto-injector (MyClic), pediatric indication and packaging, and room temperature storage, resulting in significant additional brand value.
-
Director, Business Planning And Analysis, Office Of The President (International)Pfizer 2002 - 2004New York, New York, UsSupported international operations with financial tracking, communications, process improvements.• Led corporate policy improvements including expansion of global patent filing strategy and consolidation of budgeting process, resulting in efficiency and new business opportunity.• Facilitated new business unit structure development, led planning of global senior meetings.
-
Director, Global Strategic Marketing (Oncology And Hemophilia)Wyeth Biopharma 2000 - 2003 -
Associate Director, Project Management (Oncology)Wyeth Ayerst Laboratories 1997 - 1999 -
General ManagerQuality Biotech 1989 - 1997
Elizabeth White Education Details
-
University Of RochesterCell/Cellular And Molecular Biology -
Allegheny CollegeBiology
Frequently Asked Questions about Elizabeth White
What company does Elizabeth White work for?
Elizabeth White works for Orphan Therapeutics Accelerator
What is Elizabeth White's role at the current company?
Elizabeth White's current role is Biotech Entrepreneur / Consultant / Gene Therapy / Rare Disease / Company Formation / Fundraising / Business Development / Corporate Strategy / Drug Development / Portfolio Strategy / Commercial Planning.
What schools did Elizabeth White attend?
Elizabeth White attended University Of Rochester, Allegheny College.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial